Threshold Pharmaceuticals
Threshold Pharmaceuticals is focused on the development of drugs targeting Tumor Hypoxia, a low oxygen condition found in solid tumors.
Launch date
Employees
Market cap
-
Enterprise valuation
€149—224m (Dealroom.co estimates Jan 2004.)
San Francisco California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$18.3m | Post IPO Equity | ||
$35.0m | Post IPO Equity | ||
$20.0m | Post IPO Equity | ||
$15.2m | Post IPO Equity | ||
N/A | Acquisition | ||
| Total Funding | €44.8m | ||
Related Content
Recent News about Threshold Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.